SGLT2 inhibitors can also help to restore function to SIRT3, a mitochondrial NAD+-dependent deacetylase that can inhibit epithelial–mesenchymal transition (EMT) and renal fibrosis [39], and which is suppressed by high glucose levels. This evidence concerns the gene SIRT3 and renal fibrosis.